Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis

References

• Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008;1:23–30. Review.10.1038/mi.2007.1
   PubMed Web of Science ®Google Scholar
• Costiniuk CT, Angel JB. Human immunodeficiency virus and the gastrointestinal immune system: Does highly active antiretroviral therapy restore gut immunity? Mucosal Immol. 2012;5:596–604.10.1038/mi.2012.82
   PubMed Web of Science ®Google Scholar
• MacArthur RD, DuPont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis. 2012;55:860–867.10.1093/cid/cis544
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141:1220–1230.10.1053/j.gastro.2011.06.063
   PubMed Web of Science ®Google Scholar
• Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial Translocation in Chronic Liver Diseases. Int J Microbiol. 2012; Article ID 694629, p. 12.
   Google Scholar
• French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, et al. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis. 2013;208:679–689.10.1093/infdis/jit225
   PubMed Web of Science ®Google Scholar
• Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, et al. Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol. 2014;20:16795–16810.10.3748/wjg.v20.i45.16795
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Stubblefield Park SR, Sung HC, Hardy G, Clagett B, Ignatz-Hoover J, et al. Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology. 2013;140:87–97.
   PubMed Web of Science ®Google Scholar
• Sobczak M, Fabisiak A, Murawska N, Wesołowska E, Wierzbicka P, Wlazłowski M, et al. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep. 2014;66:766–775.10.1016/j.pharep.2014.04.005
   PubMed Web of Science ®Google Scholar
• Kamat A, Ancuta P, Blumberg RS, Gabuzda D. Serological markers for inflammatory bowel disease in AIDS Patients with evidence of microbial translocation. PLoS ONE. 2010;5:e15533.10.1371/journal.pone.0015533
   PubMed Web of Science ®Google Scholar
• Soria A, Rossi M, Muscatello A, Gori A. HIV testing: A must for patients with inflammatory bowel disease? Am J Gastroenterol. 2011;106:1727–1728.10.1038/ajg.2011.186
   PubMed Web of Science ®Google Scholar
• Landy J, Gazzard B, Harbord M. Inflammatory bowel disease in HIV seropositive individuals: Analysis of a large cohort. Gastroenterology. 2008; 134: A-504.
   Web of Science ®Google Scholar
• Lautenbach E, Lichtenstein GR. Human immunodeficiency virus infection and crohn’s disease: The role of the CD4 cell in inflammatory bowel disease. J Clin Gastroenterol. 1997;25:456–459.10.1097/00004836-199709000-00013
   PubMed Web of Science ®Google Scholar
• Pospai D, René E, Fiasse R, Farahat K, Beaugery L, Lammens P, et al. Chron’s disease stable remission after human immunodeficiency virus infection. Dig Dis Sci. 1998;43:412–419.10.1023/A:1018883112012
   PubMed Web of Science ®Google Scholar
• Franke M, Kruis W, Heitz W. First manifestation of ulcerative colitis in a patient with HIV infection. Gastroenterology. 1990;98:544–545.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Snape WJ Jr. Active idiopathic ulcerative colitis in a patient with ongoing HIV-related immunodepression. Am J Gastroenterol. 1991;86:907–909.
   PubMed Web of Science ®Google Scholar
• Viazis N, Vlachogiannakos J, Georgiou O, Rodias M, Georgiadis D, Papastamopoulos V, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis. 2010;16:507–511.10.1002/ibd.21077
   PubMed Web of Science ®Google Scholar
• Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005;352:15–35. Review.10.1016/j.cccn.2004.09.001
   Google Scholar
• Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210:1228–1238.
   PubMed Web of Science ®Google Scholar
• Wiercinska-Drapalo A, Jaroszewicz J, Siwak E, Pogorzelska J, Prokopowicz D. Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul Pept. 2008;147:25–28.10.1016/j.regpep.2007.12.002
   PubMedGoogle Scholar
• Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015;29:43–51.10.1097/QAD.0000000000000511
   PubMed Web of Science ®Google Scholar
• Hoffmanová I, Sánchez D, Hábová V, Anděl M, Tučková L, Tlaskalová-Hogenová H. Serological markers of enterocyte damage and apoptosis in patients with celiac disease, autoimmune diabetes mellitus and diabetes mellitus type 2 [Epub ahead of print December 3, 2014]. Physiol Res. 2015;64:537–546.
   PubMed Web of Science ®Google Scholar
• Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111–132.
   PubMedGoogle Scholar
• Criscuoli V, Modesto I, Orlando A, Cottone M. Mesalazine for the treatment of inflammatory bowel disease. Expert Opin Pharmacother. 2013;14:1669–1678.10.1517/14656566.2013.808622
   PubMed Web of Science ®Google Scholar
• Somsouk M, Dunham RM, Cohen M, Albright R, Abdel-Mohsen M, Liegler T, et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: A randomized crossover trial. PLoS One. 2014;9:e116.
   Web of Science ®Google Scholar